Abstract
Background: long-term combined estrogen-progestin oral contraceptive pills (COCPs) are the first-line treatment for polycystic ovary syndrome (PCOS). However, this therapeutic option does not affect metabolic disorders that are more severe in women with the second PCOS phenotype thus increasing the risk of cardiometabolic complications.Aim: to assess the effect of myo-inositol and D-chiro-inositol at a 5:1 ratio on metabolic parameters in women of reproductive age with the second PCOS pathogenetic type and the disorders of carbohydrate and lipid metabolism. Patients and Methods: 60 overweight and obese women with PCOS were enrolled in this randomized prospective study. Group 1 women (n=30) received COCP and a drug containing two isoforms of inositol at a 5:1 ratio (myo-inositol 1,000 mg plus D-chiro inositol 200 mg). Group 2 women (n = 30) received COCP only. Hemostasis, lipid panel, fasting glucose level, body mass index (BMI), and waist circumference were measured before and 90 days after treatment begins. Results: in group 1, the significant (p<0.05) improvement of lipid parameters was reported as demonstrated by the reduction of the levels of total cholesterol (TC) by 16.9%, triglycerides by 15.7%, low-density lipoprotein cholesterol (LDL–C) by 17.8%, fibrinogen by 15.8%, and fasting glucose by 16.9% as well as the increase of high-density lipoprotein cholesterol (HDL–C) by 28.5%. Meanwhile, no significant changes were seen in group 2. Additionally, the reduction of waist circumference by 4.5% and BMI by 9.1% was reported in group 1. Conclusions: a medication containing myo-inositol and D-chiro-inositol at a 5:1 ratio is promising for the prevention of cardiometabolic complications in women with PCOS. Further large studies of the investigated drug are needed to demonstrate its efficacy and to assess its properties. KEYWORDS: polycystic ovary syndrome (PCOS), treatment, prevention, obesity, metabolic syndrome, lipid panel, inositol, oral contraceptive pills. FOR CITATION: Dobrokhotova Yu.E., Lapina I.A., Chirvon T.G., Taranov V.V. New prospects of the integrative therapy for polycystic ovary syndrome in women with the disorders of carbohydrate and lipid metabolism: a comparative study. Russian Journal of Woman and Child Health. 2020;3(3):169–173. DOI: 10.32364/2618-8430-2020-3-3-169-173.
Highlights
15.8%, and fasting glucose by 16.9% as well as the increase of high-density lipoprotein cholesterol (HDL–C) by 28.5%
The reduction of waist circumference by 4.5% and body mass index (BMI) by 9.1% was reported in group 1
Conclusions: a medication containing myo-inositol and D-chiro-inositol at a 5:1 ratio is promising for the prevention of cardiometabolic complications in women with polycystic ovary syndrome (PCOS)
Summary
Новые возможности интегративной терапии пациенток с синдромом поликистозных яичников и нарушениями углеводного и липидного обмена. РЕЗЮМЕ Введение: первой линией лечения женщин с синдромом поликистозных яичников (СПКЯ) является назначение эстроген-гестагенных комбинированных оральных контрацептивов (КОК) в длительном режиме. Однако такая терапевтическая стратегия не влияет на метаболические нарушения, более выраженные у пациенток со вторым патогенетическим вариантом СПКЯ, что ведет к увеличению риска кардиометаболических осложнений. Цель исследования: оценить влияние средства на основе мио- и D-хиро-инозитола в соотношении 5:1 на метаболические показатели у пациенток репродуктивного возраста со вторым патогенетическим вариантом СПКЯ и нарушением углеводного и липидного обмена. Заключение: включение в терапию пациенток с СПКЯ средства на основе мио- и D-хиро-инозитола в соотношении 5:1 представляется перспективным для профилактики у них кардиометаболических осложнений. ДЛЯ ЦИТИРОВАНИЯ: Доброхотова Ю.Э., Лапина И.А., Чирвон Т.Г., Таранов В.В.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
